🔎 Trials Near Me

Home › Leucemia mieloide acuta › Arkansas

Studi clinici su Leucemia mieloide acuta nello stato di Arkansas

13 studi su Leucemia mieloide acuta cercano partecipanti presso sedi nello stato di Arkansas.

Città nello stato di Arkansas

Testo ufficiale dello studio (inglese)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Fort Smith, Fort Smith
  • CARTI Cancer Center, Little Rock
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • University of Arkansas at Little Rock, Little Rock
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Arkansas for Medical Sciences, Little Rock
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 3
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 3
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 3
29 Days – 21 Years · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Arkansas Children's Hospital, Little Rock
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 1
Fino a 21 anni · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT05101551

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.